The era of high-quality chemical probes.

Autor: Licciardello MP; Centre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research London UK paul.workman@icr.ac.uk., Workman P; Centre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research London UK paul.workman@icr.ac.uk.; The Chemical Probes Portal UK.

Publikováno v: RSC medicinal chemistry [RSC Med Chem] 2022 Nov 28; Vol. 13 (12), pp. 1446-1459. Date of Electronic Publication: 2022 Nov 28 (Print Publication: 2022).

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.

Autor: Poon E; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Liang T; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA., Jamin Y; Division of Radiotherapy and Imaging, ICR, London, United Kingdom., Walz S; Core Unit Bioinformatics, Comprehensive Cancer Center Mainfranken and Theodor Boveri Institute, Biocenter, University of Wurzburg, Wurzburg, Germany., Kwok C; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Hakkert A; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Barker K; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Urban Z; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Thway K; Division of Molecular Pathology, ICR, London, and Royal Marsden NHS Trust, Sutton, United Kingdom., Zeid R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Hallsworth A; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Box G; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., Ebus ME; Prinses Maxima Center for Pediatric Oncology, Utrecht, Netherlands., Licciardello MP; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., Sbirkov Y; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Lazaro G; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Calton E; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Costa BM; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Valenti M; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., De Haven Brandon A; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., Webber H; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Tardif N; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Almeida GS; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Division of Radiotherapy and Imaging, ICR, London, United Kingdom., Christova R; Division of Clinical Studies and., Boysen G; Division of Clinical Studies and., Richards MW; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom., Barone G; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Ford A; Division of Molecular Pathology, ICR, London, and Royal Marsden NHS Trust, Sutton, United Kingdom., Bayliss R; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom., Clarke PA; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., De Bono J; Division of Clinical Studies and., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Blagg J; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., Robinson SP; Division of Radiotherapy and Imaging, ICR, London, United Kingdom., Eccles SA; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., Zheleva D; Cyclacel Ltd., Dundee, United Kingdom., Bradner JE; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Molenaar J; Prinses Maxima Center for Pediatric Oncology, Utrecht, Netherlands., Vivanco I; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom., Eilers M; Comprehensive Cancer Center Mainfranken and Theodor Boveri Institute, Biocenter, University of Wurzburg, Wurzburg, Germany., Workman P; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom., Lin CY; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA., Chesler L; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2020 Nov 02; Vol. 130 (11), pp. 5875-5892.

A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor.

Autor: Licciardello MP; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Ringler A; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Markt P; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Klepsch F; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Lardeau CH; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.; Christian Doppler Laboratory for Chemical Epigenetics and Anti infectives, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Sdelci S; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Schirghuber E; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.; Christian Doppler Laboratory for Chemical Epigenetics and Anti infectives, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Müller AC; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Caldera M; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Wagner A; Christian Doppler Laboratory for Molecular Stress Research in Peritoneal Dialysis, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria., Herzog R; Christian Doppler Laboratory for Molecular Stress Research in Peritoneal Dialysis, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria., Penz T; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Schuster M; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Boidol B; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.; Christian Doppler Laboratory for Chemical Epigenetics and Anti infectives, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Dürnberger G; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Folkvaljon Y; Department of Surgery and Perioperative Sciences, Urology and Andrology, Umeå University Hospital, Umeå, Sweden., Stattin P; Department of Surgery and Perioperative Sciences, Urology and Andrology, Umeå University Hospital, Umeå, Sweden.; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden., Ivanov V; Enamine Ltd., Kiev, Ukraine., Colinge J; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Bock C; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.; Max Planck Institute for Informatics, Saarland Informatics Campus, Saarbrücken, Germany., Kratochwill K; Christian Doppler Laboratory for Molecular Stress Research in Peritoneal Dialysis, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria., Menche J; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Bennett KL; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Kubicek S; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.; Christian Doppler Laboratory for Chemical Epigenetics and Anti infectives, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Publikováno v: Nature chemical biology [Nat Chem Biol] 2017 Jul; Vol. 13 (7), pp. 771-778. Date of Electronic Publication: 2017 May 22.

NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.

Autor: Licciardello MP; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Müllner MK; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Dürnberger G; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Kerzendorfer C; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Boidol B; 1] CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria [2] Christian Doppler Laboratory for Chemical Epigenetics and Antiinfectives, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Trefzer C; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Sdelci S; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Berg T; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Penz T; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Schuster M; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Bock C; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Kralovics R; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Superti-Furga G; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Colinge J; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Nijman SM; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Kubicek S; 1] CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria [2] Christian Doppler Laboratory for Chemical Epigenetics and Antiinfectives, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Publikováno v: Oncogene [Oncogene] 2015 Jul; Vol. 34 (29), pp. 3780-90. Date of Electronic Publication: 2014 Sep 29.